Veracyte, Inc. director Karin Eastham filed a Form 144 notice of proposed sale of 14,850 shares of common stock on October 27, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Seller and role: Karin Eastham, listed as a Director of Veracyte, Inc., is the person for whose account the securities are to be sold.
  • Shares proposed for sale: 14,850 shares of Veracyte common stock, with an aggregate market value of $715,770.00 as stated in the filing.
  • Approximate date of sale: October 27, 2026, on the NASDAQ exchange.
  • Source of shares: 10,000 shares acquired via exercise of stock options from the issuer on October 27, 2026; 4,850 shares acquired via Restricted Stock Units from the issuer on June 8, 2022.
  • Rule 10b5-1 plan: The filing notes a plan adoption date of May 28, 2026.
  • Shares outstanding: 80,390,731 shares of common stock outstanding, according to the filing.
  • Prior sales: No securities of the issuer were sold during the past three months by the person for whose account the securities are to be sold, per the filing.

Eastham's Proposed Share Sale: Acquisition Sources and Trading Plan Details

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Karin Eastham, a director of Veracyte, Inc. (NASDAQ:VCYT), notified regulators of a proposed sale of 14,850 shares of the company's common stock. The aggregate market value of the shares is stated in the filing as $715,770.00. The filing identifies Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as the named broker for the transaction.

The filing discloses two separate lots of shares. The first lot, consisting of 10,000 shares, was acquired on October 27, 2026, through the exercise of stock options, with the issuer named as the party from whom the shares were acquired and cash listed as the nature of payment. The second lot, consisting of 4,850 shares, was acquired on June 8, 2022, through Restricted Stock Units, also from the issuer.

The filing indicates that the proposed sale is being made in reliance on a Rule 10b5-1 written trading plan, with a plan adoption date listed as May 28, 2026. The filing further states that no securities of the issuer were sold during the past three months by the person for whose account the securities are proposed to be sold. At the time of the filing, the total shares of Veracyte common stock outstanding were reported as 80,390,731.

What Was Disclosed

Veracyte director Karin Eastham filed a Form 144 on October 27, 2026, proposing to sell 14,850 shares of common stock valued at $715,770.00, acquired through stock option exercises and Restricted Stock Units, under a Rule 10b5-1 plan adopted May 28, 2026.